European Medicines Agency recommends suspension of all buflomedil-containing medicines

Benefits of vasoactive agents do not outweigh risks of serious cardiological and neurological side effects

 

London, UK (November 17, 2011) – The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) concluded a review of the safety and efficacy of buflomedil, saying that the risks of these medicines, particularly the risks of severe cardiological and neurological adverse reactions, are greater than their limited benefits in the treatment of patients with chronic peripheral arterial occlusive disease (PAOD). The Committee therefore recommended that the marketing authorisations of all buflomedil-containing medicines be suspended in all European Union (EU) Member States where they are currently authorised.

 

Doctors should stop using buflomedil and consider alternative treatment options, including managing underlying health problems which can increase the risk of PAOD, such as diabetes, high blood pressure as well as smoking.

 

Patients using buflomedil-containing medicines should make an appointment with their doctor at a convenient time to discuss their ongoing treatment.

 

Buflomedil, a vasoactive agent, is used to treat the symptoms of peripheral arterial occlusive disease (PAOD). This is a condition where the body’s large arteries become obstructed causing symptoms such as pain and weakness, particularly in the legs. Buflomedil is used in patients with stage II PAOD, who experience severe pain when walking even relatively short distances.

 

The review of buflomedil was initiated following the suspension of the marketing authorisation in France by the French regulatory authority in February 2011.

 

The CHMP considered all available data on the benefits and risks of buflomedil, including the benefit-risk assessment carried out by France, data from clinical studies, post-marketing surveillance and published literature, as well as from poison control centres in the EU.

 

Following review of these data the Committee concluded that:

 

  • there was a risk of serious neurological and cardiac side effects in patients taking buflomedil under normal conditions of use and that risk minimisation measures such as changes to the packaging of the medicine, recommendations on adjusting the dose for patients with kidney problems and restrictions on the medicines’ use in certain patients had not been able to reduce these risks to an acceptable level.
  • due to the narrow therapeutic index (i.e. the small difference between buflomedil’s therapeutic dose and its toxic dose) there was a significant risk of adverse events, particularly in elderly patients and in patients with certain conditions such as kidney problems, which are common in PAOD.

 

  • data in support of the benefit of the medicine for patients were limited and of poor quality.

 

The Committee was therefore of the opinion that the benefits of buflomedil-containing medicines do no longer outweigh their risks, and recommended that marketing of these medicines should be suspended throughout the EU.

 

 

Notes

 

  • Buflomedil-containing medicines have been authorised in the EU since the 1970s via national procedures. Buflomedil is authorised in the form of tablets, an oral solution or a solution for injection in Austria, Belgium, Cyprus, France, Germany, Greece, Italy, Luxembourg, the Netherlands, Poland, Portugal and Spain under the invented name Loftyl and other trade names.

 

  • The review was carried out under Article 107 of Directive 2001/83/EC. This type of procedure is triggered when a Member State varies, suspends or revokes the marketing authorisation for a medicine in its territory because of a safety issue.

 

  • The CHMP’s recommendation will be sent to the European Commission for the adoption of a decision.

 

  • All other opinions and documents adopted by the CHMP at their November 2011 plenary meeting will be published on Friday, 18 November 2011 at 12.00 noon UK time on a dedicated web page.

 

 


European Medicines Agency (EMA), 17.11.2011 (tB).

MEDICAL NEWS

Overly restrictive salt intake may worsen outcomes for common form…
COVID-19 vaccines are estimated to have prevanented 20 million deaths…
Novel sleep education learning modules developed for nurse practitioners
Scientists discover how salt in tumours could help diagnose and…
Inadequate sequencing of SARS-CoV-2 variants impedes global response to COVID-19

SCHMERZ PAINCARE

Aktuelle Versorgungssituation der Opioidtherapie im Fokus
Individuelle Schmerztherapie mit Opioiden: Patienten im Mittelpunkt
Versorgung verbessern: Deutsche Gesellschaft für Schmerzmedizin fordert die Einführung des…
Pflegeexpertise im Fokus: Schmerzmanagement nach Operationen
Versorgung verbessern: Bundesweite Initiative der Deutschen Gesellschaft für Schmerzmedizin zu…

DIABETES

Kaltplasma bei diabetischem Fußsyndrom wirkt via Wachstumsfaktoren
Typ-1-Diabetes: InRange – auf die Zeit im Zielbereich kommt es…
Suliqua®: In komplexem Umfeld – einfach besser eingestellt
Suliqua®: Überlegene HbA1c-Senkung  im Vergleich zu Mischinsulinanalogon
„Wissen was bei Diabetes zählt: Gesünder unter 7 PLUS“ gibt…

ERNÄHRUNG

Mangelernährung gefährdet den Behandlungserfolg — DGEM: Ernährungsscreening sollte zur klinischen…
Wie eine Diät die Darmflora beeinflusst: Krankenhauskeim spielt wichtige Rolle…
DGEM plädiert für Screening und frühzeitige Aufbautherapie: Stationäre COVID-19-Patienten oft…
Führt eine vegane Ernährungsweise zu einer geringeren Knochengesundheit?
Regelmässiger Koffeinkonsum verändert Hirnstrukturen

ONKOLOGIE

Krebspatienten unter Immuntherapie: Kein Hinweis auf erhöhtes Risiko für schwere…
Aktuelle Kongressdaten zum metastasierten Mammakarzinom und kolorektalen Karzinom sowie Neues…
Mehr Lebensqualität für onkologische Patient:innen durch bessere Versorgung: Supportivtherapie, Präzisionsonkologie,…
WHO veröffentlicht erste Klassifikation von Tumoren im Kindesalter
Anti-Myelom-Therapie mit zusätzlich Daratumumab noch effektiver

MULTIPLE SKLEROSE

Aktuelle Daten zu Novartis Ofatumumab und Siponimod bestätigen Vorteil des…
Multiple Sklerose durch das Epstein-Barr-Virus – kommt die MS-Impfung?
Neuer Therapieansatz für Multiple Sklerose und Alzheimer
„Ich messe meine Multiple Sklerose selbst!“ – Digitales Selbstmonitoring der…
Stellungnahme zur 3. Impfung gegen SARS-CoV2 bei Personen mit MS

PARKINSON

Alexa, bekomme ich Parkinson?
Meilenstein in der Parkinson-Frühdiagnose
Parkinson-Erkrankte besonders stark von Covid-19 betroffen
Gangstörungen durch Kleinhirnschädigung beim atypischen Parkinson-Syndrom
Parkinson-Agenda 2030: Die kommenden 10 Jahre sind für die therapeutische…